Research & Development

Is Novo Nordisk the Best Play in a Fractured Stock Market?
Research & Development Is Novo Nordisk the Best Play in a Fractured Stock Market?

Novo Nordisk now trades at roughly 14 times earnings, representing a significant discount compared to its primary rival, Eli Lilly, which commands a multiple of 34 times earnings. This stark valuation gap emerges at a time when the broader financial landscape appears increasingly disconnected from

MRD Testing Transforms Colorectal and Bladder Cancer Care
Research & Development MRD Testing Transforms Colorectal and Bladder Cancer Care

Molecular evidence of cancer persisting in the bloodstream after curative-intent surgery offers a high-resolution view of a patient’s true disease status. This breakthrough marks a departure from traditional oncology, where clinicians often wait for visible signs of relapse on a scan or an

BioNTech Cancer Trial Misses Goal but Continues to Study Survival
Research & Development BioNTech Cancer Trial Misses Goal but Continues to Study Survival

The global biotechnology market currently stands at a transformative crossroad as the latest findings from BioNTech’s clinical pipeline indicate that the roadmap for oncology is significantly more nuanced than the rapid success of COVID-19 vaccines once suggested. This announcement, while initially

Can NKR Antagonists Help Treat and Prevent Breast Cancer?
Research & Development Can NKR Antagonists Help Treat and Prevent Breast Cancer?

The intersection of reproductive health and oncology reached a significant turning point this year as clinical evidence began to suggest that medications used to calm the brain’s thermostat could also serve as a potent defense against tumor growth. For several years, the medical community has

How Will the Roche-Hansoh $15B ADC Deal Reshape Oncology?
Research & Development How Will the Roche-Hansoh $15B ADC Deal Reshape Oncology?

The $15 billion expansion of the Roche-Hansoh partnership signals a massive shift toward multi-program antibody-drug conjugate portfolios rather than traditional single-asset licensing deals. This momentous agreement, finalized in late 2026, represents a fundamental restructuring of how global

Can CAR T-Cell Therapy Redefine Early Relapsed Myeloma Care?
Research & Development Can CAR T-Cell Therapy Redefine Early Relapsed Myeloma Care?

Manufacturing failures can occur if patients receive lymphodepleting agents like bendamustine too close to the collection of their therapeutic T cells. This biological reality creates a high-stakes environment for oncologists managing relapsed/refractory multiple myeloma, where the timing of every

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later